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Abstract
Background: Risk prediction for CVD events has been shown to vary according to current smoking status, pack-
years smoked over a lifetime, time since quitting and age at quitting. The latter two are closely and inversely
related. It is not known whether the age at which one quits smoking is an additional important predictor of CVD
events. The aim of this study was to determine whether the risk of CVD events varied according to age at quitting
after taking into account current smoking status, lifetime pack-years smoked and time since quitting.
Findings: We used the Cox proportional hazards model to evaluate the risk of developing a first CVD event for a
cohort of participants in the Framingham Offspring Heart Study who attended the fourth examination between
ages 30 and 74 years and were free of CVD. Those who quit before the median age of 37 years had a risk of CVD
incidence similar to those who were never smokers. The incorporation of age at quitting in the smoking variable
resulted in better prediction than the model which had a simple current smoker/non-smoker measure and the one
that incorporated both time since quitting and pack-years. These models demonstrated good discrimination,
calibration and global fit. The risk among those quitting more than 5 years prior to the baseline exam and those
whose age at quitting was prior to 44 years was similar to the risk among never smokers. However, the risk among
those quitting less than 5 years prior to the baseline exam and those who continued to smoke until 44 years of
age (or beyond) was two and a half times higher than that of never smokers.
Conclusions: Age at quitting improves the prediction of risk of CVD incidence even after other smoking measures
are taken into account. The clinical benefit of adding age at quitting to the model with other smoking measures
may be greater than the associated costs. Thus, age at quitting should be considered in addition to smoking
status, time since quitting and pack-years when counselling individuals about their cardiovascular risk.
Introduction
CVD risk associated with smoking varies not only with
smoking status but also with intensity and duration of
smoking or smoking pack-years, time since quitting and
age at quitting. Many studies have examined the lag in
health benefit of smoking cessation measured by time
since quitting and occurrence of a CVD event [1-8].
However age at quitting also affects the health benefits
of smoking cessation [9,10]. The risks of mortality and
smoking-related disease increase with age at quitting.
However, the role of age at quitting as a predictor of
CVD risk in the presence of time since quitting and
pack-years is unclear. As CVD is more common among
elderly people it is likely that age at quitting and time
since quitting, inversely correlated, influence CVD risk
in opposite directions.
This study explores whether and how age at quitting
influences risk of CVD incidence, using data from the
Framingham Offspring Heart Study. It uses a smoking
status variable with and without incorporating other
smoking variables such as time since quitting among * Correspondence: haider.mannan@monash.edu
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while controlling for common risk factors.
Methods & Results
Study Design and Sample
The Framingham Offspring Heart Study details for
design, selection criteria, examination procedures and
criteria for CVD events have been described elsewhere
[11-15]. Participants were eligible for the present study
if at examination 4 (1988 to 1992) they were CVD-free
and aged 30-74 with nonmissing data on covariates. The
final study sample consisted of 3751 participants (mean
age 51.61; 1937 women).
Measurement of CVD Risk Factors
The risk factors included were smoking status with var-
ious definitions (expanded below), systolic and diastolic
blood pressure (SBP & DBP), total cholesterol/high-den-
sity-lipoprotein (HDL) ratio or both (depending on
which provided a better prediction of outcome), age,
sex, diabetes status and body-mass index (BMI). Smok-
ing status was initially defined as a dichotomous current
smoker/non-smoker variable. The other definitions of
smoking status included four, six and eight categories.
The four category smoking status variable was defined
as: never smokers, former smokers with age at quitting
below 37 years, former smokers with age at quitting of
37 years or older, and current smokers. The six category
smoking status variable was defined as: never smokers,
former smokers with time since quitting 5 years or less
and over 5 years and current smokers with under 20,
20-39, and 40 or more pack-years where current pack-
years were calculated by dividing the number of cigar-
ettes being smoked per day by 20 to obtain an estimate
of “packs” and multiplying this by the number of years a
person was a smoker. The eight category smoking status
variable was defined as: never smokers, past smokers
into 4 groups with two levels of age at quitting (≤44,
>44 years) at each of two levels of time since quitting
(≤5, and >5 years) and current smokers with under 20,
20-39, and 40 or more pack-years.
Blood pressure was the average of two physician-
obtained measures. Cholesterol and various smoking
measures were based on standardized enzymatic meth-
ods and self-report, respectively. Diabetes was defined as
a fasting glucose ≥126 mg/dL. Age at quitting and time
since quitting were calculated at examination 4 by com-
bining smoking status information at each examination
with history of smoking status from examination 1 [8].
Development & assessment of predictive models
The Cox proportional-hazards model [16] was used to
relate risk factors to the risk of CVD incidence during fol-
low-up from examinations 4 to 7. The assumption of
proportionality of hazards was satisfied; tested by taking
interaction between a covariate and log (survival time) [17]
and plotting Schoenfeld residuals against survival time.
To improve the interpretability of the predictive mod-
els we categorized time since quitting, age at quitting and
pack-years. It was observed that the lag time for a benefi-
cial effect of smoking cessation on risk of CVD incidence
was five years after which the risk stabilized [8]. In the lit-
erature there is no maximum age for quitting without
increasing the risk of a CVD event compared to a never
smoker and there was no apparent cutpoint to dichoto-
mise this variable as the predicted time to the onset of a
CVD event declined almost linearly with age at quitting
(results not shown). Thus the median, shown by simula-
tion to result in minimum loss in efficiency [18], was
used to dichotomise age at quitting.
Four models were fitted for the outcome. Each
included a composite measure of smoking status and all
other risk factors found to be significantly related to the
outcome. Model 1 included smoking status as a simple
current smoker/non-smoker variable with current non-
smoker as the reference category. To incorporate the
effect of age at quitting into smoking status, quitters
were separated from current non-smokers and categor-
ized by age at quitting in Model 2, which incorporated
smoking status with categories <37 and ≥37 years for age
at quitting, never smokers and current smokers. To
examine whether incorporating age at quitting to smok-
ing status improved risk prediction, Model 2 was com-
pared to Model 1. To examine whether incorporating age
at quitting improves risk prediction to a model which
already includes time since quitting and pack-years in
smoking status, Models 3 and 4 were fitted and com-
pared. Model 3 incorporated smoking status that
included categories for never smokers, ≤5 and >5 years
for time since quitting, and <20, 20-39 and 40+ for pack-
years. Other categorizations for pack-years and time
since quitting were found to be less effective in terms of
predictive ability. Model 4 added age at quitting to
Model 3 with smoking status having six categories -
never smoker, current smoker, and past smokers quitting
≤5 years and whose age at quitting was ≤ 44 or >44 years,
and those quitting >5 years and whose age at quitting
was ≤ 44 or >44 years. Compared with Model 2 age at
quitting was categorized differently because for the initial
categorization of age at quitting at < 37 and ≥37 years
there were inadequate numbers of cases in one of the
joint categories of this variable with time since quitting
resulting in inefficient estimation of its regression coeffi-
cient. The other cutpoints prior to reaching age 44 pro-
duced the same result until the cutpoint reached age 44
which did not yield inadequate number of cases in any of
the joint categories. In Models 2 through 4 the reference
category for smoking status was never smoker.
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improvement between two nested models we used Har-
rell’s c statistic [19,20] and a test for difference in two
correlated c statistics [21]. Large ‘independent’ associa-
tion of the new covariate with the outcome is required
to result in a meaningfully larger c statistic [22-24] for
models possessing reasonably good discrimination, and
the c statistic does not assist a physician in treatment
decisions about an individual [25,26] while reclassifica-
tion statistics NRI [27] and IDI [27] do [25,26]. Thus,
we used the latter to supplement c-statistic analyses
[27,28]. For calculating NRI we assessed risk reclassifica-
tion [27] by sorting the predicted risk for each model
into four clinically meaningful categories (<6%, 6% to <
10%, 10% to < 20%, and ≥ 20%). The benefit and cost of
using a new model compared to a baseline model can
be measured by the proportions of subjects with and
without subsequent events, respectively, who are classi-
fied as high risk (eg. ≥ 20%) according to the new model
[26]. There was negligible overoptimism in c and NRI
estimates obtained by bootstrapping as these were less
than 0.007 and 0.005 respectively.
For assessing calibration of the fitted models and
improvement in global fit between two nested models
we computed the Hosmer-Lemeshow statistic and its
modification [28] and likelihood ratio test respectively.
Neither Models 3 nor 4 included current age as a cov-
ariate because it had exact collinearity with time since
quitting and age at quitting.
Results
Sample characteristics
The sample risk factor characteristics at baseline exami-
nation 4 are shown in Table 1. The sample consists of
26.7% never smokers, 48.4% quitters (15.1% of whom
quit within 5 years of the baseline measurement and
33.1% of whom quit before age 37 years), and 14.5%
current smokers (of whom 16.6% have exposure ≥40
pack-years).
Model comparisons
Table 2 shows that Model 2 improved predictive ability
significantly compared to Model 1. Model 3 performed
well in terms of model discrimination and overall fit but
less well in terms of calibration. Model 4 performed
well on all model performance indicators; significantly
improving predictive ability compared to Model 3
(Table 3). Thus, age at quitting was an independent pre-
dictor of risk of CVD incidence regardless of including
time since quitting and pack-years in the model.
Compared to never smokers, the risk of CVD incidence
based on Model 2 was 7.3% higher (RR = 1.073, 95% CI
0.804 ~ 1.433) for those who quit before age 37 years and
58.1% higher (RR = 1.581, 95% CI 1.193 ~ 2.094) for those
who quit at least at age 37 years (Table 4). For the former
category the relative risk was not significantly different
from the never smokers while for the latter category it
was. Based on the final model (Model 4), the risk among
those quitting more than 5 years prior to the baseline
exam and whose age at quitting was 44 years or less was
close to never smokers. Risk among those quitting within
5 years prior to the baseline exam and whose age at quit-
ting was over 44 years was about three times higher than
that of never smokers (Table 5).
Reclassification of subjects
This section describes how many subjects were reclassified
overall and with respect to ‘high risk’ category of ≥ 20%
when we compared the preferred full model against the
reference model. Comparing Model 2 against Model 1, for
participants who experienced a CVD event, the net gain in
reclassification proportion was significantly different from
zero (p = 0.0113) (Table 6) and significant for participants
who did not experience an event (p = 0.0025) and for all
participants (p = 0.0112). For those who experienced a
CVD event, using Model 4 rather than Model 3 did not
improve net gain in reclassification proportion signifi-
cantly (p = 0.2935) (Table 7). The result was similar for
Table 1 Summary Statistics for Risk Factors (at exam 4)
Used in Risk Models for Total Population Characteristics
Summary statistic
Sex, N (%)
- Females 1937 (51.6)
- Males 1814 (48.4)
Age (years), mean (SD) 51.61 (9.6)
Total-C (mg/dL), mean (SD) 206.30 (39.2)
HDL-C (mg/dL), mean (SD) 49.52 (14.8)
Systolic blood pressure (mmHg), mean (SD) 127.11 (18.9)
Diastolic blood pressure (mmHg), mean (SD) 79.25 (10.0)
Triglycerides (meq/liter), mean (SD) 125.92 (101.3)
Alcohol (ounce), mean (SD) 2.89 (4.4)
Total cholesterol (mg/dl), mean (SD) 206.31(39.2)
HDL cholesterol (mg/dl), mean (SD) 49.52 (14.8)
Total/HDL cholesterol ratio, mean (SD) 4.54 (1.7)
Body mass index (kg/m
2), mean (SD) 26.86 (4.8)
Never smoking, N (%) 1002 (26.7)
Past smoking, N (%) 1817 (48.4)
Time since quitting ≤ 5 years, N (%) 565 (15.1)
Time since quitting >5 years, N (%) 1252 (33.4)
Age at quitting <37 years, N (%) 1240 (33.1)
Age at quitting > = 37 years, N (%) 577 (15.4)
Current smoking, N (%) 932 (24.9)
Pack years <20, N (%) 105 (2.8)
Pack years 20-39, N (%) 206 (5.5)
Pack years 40+, N (%) 621 (16.6)
Diabetes, N (%) 163 (4.4)
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Page 3 of 9Table 2 Improvement in CVD risk prediction due to including age at quitting among past smokers in Model 1
Likelihood ratio Value Degrees of freedom p-value
Vs model 1 11.4732 2 0.0032
Difference between two correlated C Estimate (SE) 95% CI Chi-square p-value
Vs model 1 0.0047(0.0022) 0.0004, 0.0090 4.5340 0.0332
Estimate 95% CI Z p-value
NRI
Vs model 1 0.0512 0.0117, 0.0906 2.5343 0.0113
IDI
Vs model 1 0.0014 -0.0010,0.0037 1.1012 0.2707
Note: Model 1 included current smoking status, systolic and diastolic blood pressure, total cholesterol/HDL ratio, triglycerides, age, sex and diabetes status.
Table 3 Improvement in CVD risk prediction due to including age at quitting among past smokers in Model 3
Likelihood ratio Value Degrees of freedom p-value
Vs model 3 25.8845 2 <0.0001
Difference between two correlated C Estimate (SE) 95% CI Chi-square p-value
Vs model 3 0.0079(0.0036) 0.0008,0.0150 4.7266 0.0297
Estimate 95% CI Z p-value
NRI
Vs model 3 0.0294 -0.0111,0.0701 1.4192 0.1558
IDI
Vs model 3 0.0029 0.0001, 0.0057 2.0362 0.0417
Note: Model 3 incorporated smoking status that included categories for never smokers (reference group), ≤5 and >5 years for time since quitting, and <20, 20-39
and 40+ for pack-years, systolic and diastolic blood pressure, total cholesterol/HDL ratio, triglycerides, age, sex and diabetes status.
Table 4 Risk equation with a simple current/non-smoker smoking status variable (Model 1)
Variable Parameter Estimate Standard Error Chi-Square P value Hazard Ratio 95% CI
Sex 0.6391 0.1119 32.6222 <.0001 1.895 1.522 2.360
Age 0.0768 0.0069 123.1031 <.0001 1.080 1.065 1.095
Sbp 0.0142 0.0036 14.9743 0.0001 1.014 1.007 1.022
Dbp -0.0176 0.0069 6.3866 0.0115 0.983 0.969 0.996
Total/HDL ratio 0.2127 0.0347 37.4452 <.0001 1.237 1.156 1.324
Diabetes 0.8101 0.1518 28.4764 <.0001 2.248 1.670 3.028
Trglycerides -0.0015 0.0005 7.2971 0.0069 0.998 0.997 1.000
Current smoker 0.5594 0.1251 19.9779 <.0001 1.750 1.369 2.236
Test Total Event Censord % Censord
3751 383 3368 89.79
Chi-Square DF P value
Likelihood Ratio 437.1565 8 <. 0001
Hosmer Lemeshow 18.6207 9 0.0286
Modified HL 17.4569 9 0.0420
Estimate SE 95% CI
C statistic 0.8038 0.0109 0.7825,0.8251
Note: The reference categories for sex, diabetes and the smoking variable are female, no diabetes and non-current smoker respectively.
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Variable Parameter Estimate Standard Error Chi-Square P value Hazard Ratio 95% CI
Sex 0.5967 0.1133 27.7286 <.0001 1.816 1.454 2.268
Age 0.0730 0.0070 107.9667 <.0001 1.076 1.061 1.091
Sbp 0.0140 0.0036 14.7801 0.0001 1.014 1.007 1.021
Dbp -0.0172 0.0069 6.1574 0.0131 0.983 0.970 0.996
Total/HDL ratio 0.2148 0.0354 36.7663 <.0001 1.240 1.157 1.329
Diabetes 0.7941 0.1520 27.2897 <.0001 2.213 1.642 2.981
Trglycerides -0.0016 0.0005 8.2076 0.0042 0.998 0.997 0.999
Current smoker 0.7248 0.1505 23.1684 <.0001 2.064 1.537 2.773
Age at quitting
<37 0.0708 0.1474 0.2307 0.6310 1.073 0.804 1.433
> = 37 0.4578 0.1435 10.1778 0.0014 1.581 1.193 2.094
Test Total Event Censored % Censored
3751 383 3368 89.79
Chi-Square DF P value
Likelihood Ratio 448.6297 10 <.0001
Hosmer Lemeshow 11.3628 9 0.2516
Modified HL 10.5026 9 0.3113
Estimate SE 95% CI
C statistic 0.8085 0.0108 0.7873, 0.8296
Note: The reference categories for sex, diabetes and the smoking variable are female, no diabetes and never smoker respectively.
Table 6 Risk equation incorporating time since quitting and pack-years into smoking status (Model 3)
Variable Parameter Estimate Standard Error Chi-Square P value Hazard Ratio 95% CI
Sex 0.66172 0.11252 34.5854 <.0001 1.938 1.555 2.416
Sbp 0.03508 0.00306 131.2240 <.0001 1.036 1.030 1.042
Dbp -0.04076 0.00621 43.1167 <.0001 0.960 0.948 0.972
Total/HDL ratio 0.22727 0.03592 40.0381 <.0001 1.255 1.170 1.347
Diabetes 0.88176 0.15423 32.6873 <.0001 2.415 1.785 3.268
Trglycerides -0.00170 0.00059 8.2356 0.0041 0.998 0.997 0.999
Time since quitting
< = 5 years 0.75854 0.18123 17.5189 <.0001 2.135 1.497 3.046
>5 years 0.13762 0.13059 1.1106 0.2920 1.148 0.888 1.482
Pack years
<20 0.15632 0.34319 0.2075 0.6487 1.169 0.597 2.291
20-39 0.50078 0.21593 5.3785 0.0204 1.650 1.081 2.519
40+ 0.81008 0.16219 24.9470 <.0001 2.248 1.636 3.089
Test Total Event Censored % Censored
3751 383 3368 89.79
Chi-Square DF P value
Likelihood Ratio 324.1494 11 <0.0001
Hosmer Lemeshow 11.4700 9 0.2448
Modified HL 11.0293 9 0.2737
Estimate SE 95% CI
C statistic 0.7601 0.0130 0.7346, 0.7856
Note: The reference categories for sex, diabetes and the smoking variable are female, no diabetes and never smoker respectively.
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and for all participants (p = 0.1558).
Table 8 shows that based on Model 2 instead of
Model 1, 16.5% of those developing a CVD event would
have moved up to the ‘high risk’ category of ≥20% while
of those not having a CVD event 9.4% would have
moved to this risk category, the difference of which is
highly significant (p < 0.0001). Similarly, Table 9 shows
that if we had used Model 4 rather than Model 3, 14.6%
of those who develop CVD would be appropriately
assessed for their cardiovascular risk while only 7.6% of
those who do not develop CVD would be falsely
assessed for their cardiovascular risk, the difference of
which is highly significant (p < 0.0001).
Sensitivity of the results
We have adjusted for all major confounders of smoking
to address confounding bias in the risk models. To
address the possibility of distortion due to medical
treatments affecting the risk of a CVD event we found
that the regression coefficients of the models were fairly
insensitive to the inclusion of cardioactive medications.
To address the possibility of reverse causation, we
excluded from the baseline cohort those with a cancer
history and other non-CVD conditions. This did not
substantially influence the results. Sub-analyses con-
ducted by excluding from baseline cohort those smokers
who quit after examination 4 and those quitters who
took up smoking after examination 4, and later those
current smokers from baseline cohort whose pack-years
changed substantially in subsequent examinations did
not influence our results.
Merits and demerits of this study
The study’s key strength is that it not only evaluates
improvement in predicting CVD risk when models
incorporate age at quitting but also quantifies the pro-
portions of people receiving clinical benefits and costs.
Table 7 Risk equation for CVD incidence incorporating age at quitting, time since quitting & pack-years into smoking
status (Model 4)
Variable Parameter Estimate Standard Error Chi-Square P value Hazard Ratio 95% CI
Sex 0.66579 0.11303 34.6954 <.0001 1.946 1.559 2.429
Sbp 0.03269 0.00315 107.7472 <.0001 1.033 1.027 1.040
Dbp -0.03884 0.00632 37.8124 <.0001 0.962 0.950 0.974
Total/HDL ratio 0.22400 0.03635 37.9841 <.0001 1.251 1.165 1.343
Diabetes 0.85100 0.15482 30.2145 <.0001 2.342 1.729 3.172
Trglycerides -0.00185 0.00061 9.1876 0.0024 0.998 0.997 0.999
Pack-years
< = 19 0.15082 0.34314 0.1932 0.6603 1.163 0.593 2.278
20-39 0.48640 0.21593 5.0743 0.0243 1.626 1.065 2.483
40+ 0.81617 0.16208 25.3579 <.0001 2.262 1.646 3.108
Time since quitting
< = 5 years & Age at quitting
≤ 44 -0.9483 0.71256 1.7711 0.1832 0.387 0.096 1.566
>44 1.0505 0.18672 31.6533 <.0001 2.859 1.983 4.123
Time since quitting
>5 years &
Age at quitting
≤ 44 -0.1047 0.1595 0.4315 0.5113 0.901 0.659 1.231
>44 0.5923 0.1789 10.9580 0.0009 1.808 1.273 2.568
Test Total Event Censored % Censored
3751 383 3368 89.79
Chi-Square DF P value
Likelihood Ratio 347.7915 13 <.0001
Hosmer Lemeshow 6.5337 9 0.6855
Modified HL 6.1388 9 0.7259
Estimate SE 95% CI
C statistic 0.7680 0.0130 0.7426, 0.7934
Note: The reference categories for sex, diabetes and the smoking variable are female, no diabetes and never smoker respectively.
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Page 6 of 9Table 8 Reclassification table for risk of CVD incidence between the model with age at quitting incorporated into
smoking status (Model 2) and the model with a current/non-smoker smoking measure (Model 1) as the reference
model
Model 1 Model 2
Frequency (Row per cent) <6% 6-<10% 10-<20% > = 20% Total
Participants who experience a CVD Event
<6% 158 16 0 0 174
6-<10% 8 53 12 0 73
10-<20% 0 5 60 6 71
> = 20% 0 0 8 57 65
Total 166 74 80 63 383
Net gain in reclassification proportion (p-value) 0.0339 (0.0796)
Participants who do not experience a CVD Event
<6% 1750 53 0 0 1803
6-<10% 75 469 67 0 611
10-<20% 0 79 499 36 614
> = 20% 0 0 60 280 340
Total 1825 601 626 316 3368
Net gain in reclassification proportion (p-value) 0.0172 (0.0025)
NRI (p-value) 0.0511 (0.0112)
Overall net gain in reclassification proportion
with respect to risk category > = 20%(p-value)
0.0019 (0.8518)
Overall gross gain in reclassification proportion
with respect to risk category > = 20%(p-value)
0.0263 (<0.0001)
Table 9 Reclassification table for risk of CVD incidence between the model with age at quitting, time since quitting
and pack-years incorporated into smoking status (Model 4) and a reduced model without age at quitting (Model 3) as
the reference model
Model 3 Model 4
Frequency (Row per cent) <6% 6- < 10% 10- < 20% > = 20% Total
Participants who experience a CVD Event
<6% 164 13 0 0 177
6- < 10% 10 56 12 0 78
10- < 20% 1 5 57 8 71
> = 20% 1 0 8 48 57
Total 176 74 77 56 383
Net gain in reclassification proportion (p-value) 0.0208 (0.2935)
Participants who do not experience a CVD Event
<6% 1402 85 0 0 1487
6- < 10% 83 742 64 0 889
10- < 20% 25 84 596 44 749
> = 20% 10 2 18 213 243
Total 1520 913 678 257 3368
Net gain in reclassification proportion (p-value) 0.0086 (0.1545)
NRI (p-value) 0.0294 (0.1558)
Overall net gain in reclassification proportion with
respect to risk category > = 20%(p-value)
0.0015 (0.8888)
Overall gross gain in reclassification proportion
with respect to risk category > = 20%(p-value)
0.0339 (<0.0001)
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able was not possible as the same number of CVD
events was prevented by the full and reduced models.
Also, as the Framingham cohort has an ethnically white
predominance the generalizability of our models to
other ethnic groups is unknown.
Conclusion
The incorporation of age at quitting in smoking status
resulted in better prediction compared to the model
which had a current smoker/non-smoker measure and to
the model which incorporated both time since quitting
and pack-years in smoking status. Thus, age at quitting
was an independent predictor of CVD incidence even
after accounting for time since quitting and pack-years.
We also showed that if we had incorporated age at quit-
ting in smoking status instead of a current/non-smoker
measure, a significantly higher proportion of those devel-
oping a CVD event would have moved up to the ‘high
risk’ category compared to those not having a CVD event
who moved up to this category. The result was similar if
the model added age at quitting in smoking status which
already incorporated time since quitting and pack-years.
The former would be appropriately treated while the latter
would be falsely treated if we included age at quitting in
smoking status. Those appropriately treated can benefit
from additional screening for CVD risk and would require
more aggressive intervention for smoking cessation [29]
and would thus aid in preventing more deaths. However,
this benefit would be at the cost of falsely identifying peo-
ple who do not develop CVD as high risk who may unne-
cessarily receive additional screening and may cause
undue stress and burden to the smoking cessation pro-
grams. From a CVD prevention perspective the benefits
associated with smoking cessation clearly outweigh the
costs for CVD screening and smoking cessation programs.
Age at quitting should be taken into account, as well as
other smoking measures, when counselling individuals
about their cardiovascular risk.
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